NDAORALSOLUTION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENYLIN is an oral solution containing diphenhydramine hydrochloride (first-generation antihistamine) and pseudoephedrine hydrochloride (decongestant) for symptomatic relief of cold and allergy symptoms. The combination works by blocking histamine receptors to reduce itching, sneezing, and runny nose while pseudoephedrine constricts nasal blood vessels to relieve congestion.
PRE_LAUNCH
Pre-launch status suggests active planning and team buildup for commercialization; career opportunities in launch strategy, supply chain, and field preparation are likely active.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BENYLIN during pre-launch offers hands-on exposure to OTC product commercialization, market entry strategy, and competitive positioning in a mature therapeutic category. This role suits professionals seeking to build launch execution experience and retail channel expertise at Pfizer's consumer health division.
Brand ManagerProduct Manager
Worked on BENYLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.